Drug policy impacts regional trends of ezetimibe use

June 5, 2014
Drug policy impacts regional trends of ezetimibe use

(HealthDay)—Within Canada, regional variation has been noted in ezetimibe use, which is associated with the restrictiveness of publicly-funded drug formularies, according to a study published online June 3 in Circulation: Cardiovascular Quality and Outcomes.

Lingyun Lu, Pharm.D., from the Western University of Health Sciences in Pomona, Calif., and colleagues conducted a population-level cohort study to examine ezetimibe use in four provinces in Canada. The provinces had a gradient in the restrictiveness of ezetimibe in publicly-funded formularies (most to least restrictive: British Columbia, Alberta, Quebec, and Ontario). Use was examined using IMS Health Canada's data from June 2003 to December 2012.

The researchers observed in ezetimibe use patterns. The lowest monthly increasing rate was seen in British Columbia (most restrictive), which increased from $261 (Canadian dollars) to $21,926 from June 2003 to December 2012 ($190/100,000 population/month). In contrast, the least restrictive Ontario had the most rapid monthly increase, from $223 to $74,030 ($647/100,000 population/month). Quebec and Alberta had intermediate increases, from $130 to $59,690 ($522/100,000 population/month) and from $356 to $37,604 ($327/100,000 population/month), respectively.

"Ezetimibe use remains common, increasing during the past decade," the authors write. "The gradient in use was related to variability in restrictiveness of the provincial formularies, illustrating the potential of a policy response gradient that may be used to more effectively manage medication use."

Several authors disclosed financial ties to the pharmaceutical, medical device, and insurance industries.

Explore further: Significantly improved chance of heart attack survival with high-potency statin treatment

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Significantly improved chance of heart attack survival with high-potency statin treatment

February 20, 2014
(Medical Xpress)—A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking ...

Statins for kidney disease patients: Protection for the heart but no effects on kidneys

May 1, 2014
Lowering LDL cholesterol through statin-based treatment did not slow kidney disease progression within five years in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The ...

Evolocumab superior to ezetimibe in lowering LDL cholesterol

March 31, 2014
Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable ...

Antibody combined with statin results in further reduction of cholesterol levels

May 13, 2014
Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition of the human monoclonal antibody evolocumab resulted in additional lowering of low-density lipoprotein cholesterol (LDL-C) ...

Elevated cholesterol levels: Benefit of ezetimibe is not proven

September 14, 2011
Elevated blood cholesterol levels are regarded as a risk factor for heart attacks and other cardiovascular diseases. However, this does not necessarily mean that every cholesterol-lowering drug can also prevent heart attacks. ...

Recommended for you

Southern diet could be deadly for people with heart disease

July 12, 2018
People with a history of heart disease who eat a traditional Southern diet are more likely to die than those who follow a Mediterranean dietary pattern, according to new research.

Late-life high blood pressure may harm the brain, study says

July 11, 2018
Decades ago, hundreds of nuns and priests made an extraordinary decision: They agreed to donate their brains upon death to science, hoping to help solve mysteries about Alzheimer's and other diseases. Now, a study that used ...

Multivitamins do not promote cardiovascular health

July 10, 2018
Taking multivitamin and mineral supplements does not prevent heart attacks, strokes or cardiovascular death, according to a new analysis of 18 studies published in Circulation: Cardiovascular Quality and Outcomes, an American ...

Mobile health devices diagnose hidden heart condition in at-risk populations

July 10, 2018
Wearable mobile health devices improved the rate of diagnosis of a dangerous and often hidden heart condition called atrial fibrillation (AFib), according to a first of its kind, home-based clinical study conducted in part ...

Chronic heart disease poses high financial burden to low-income families

July 3, 2018
The financial burdens of long-term care for a family member with atherosclerotic cardiovascular disease (ASCVD) disproportionately affect low-income American families, even those who have insurance, found researchers at Yale ...

Women with high blood pressure during pregnancy more likely to develop CVD risk factors

July 2, 2018
Preeclampsia and gestational hypertension are common pregnancy complications involving high blood pressure that develops for the first time during pregnancy and returns to normal after delivery. Previous studies have shown ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.